Mackay Shields LLC’s Aimmune Therapeutics AIMT Stock Holding History

Mackay Shields LLC’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-39,891	Closed	-$1.34M	–	1548
2019 Q4	$1.34M	Sell	39,891 -16,000	-29%	-$447K	0.01%	1000
2019 Q3	$1.17M	Sell	55,891 -13,300	-19%	-$272K	0.01%	1076
2019 Q2	$1.44M	Buy	69,191 +49,012	+243%	+$1.01M	0.01%	1029
2019 Q1	$451K	Sell	20,179 -2,500	-11%	-$58.9K	﹤0.01%	1199
2018 Q4	$542K	Sell	22,679 -2,521	-10%	-$65.2K	﹤0.01%	1122
2018 Q3	$687K	Buy	25,200 +9,000	+56%	+$255K	0.01%	954
2018 Q2	$435K	Buy	+16,200	New	+$496K	﹤0.01%	1120

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Mackay Shields LLC's AIMT Position: Q1 2020 in Review

Mackay Shields LLC sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 39,891 shares — an estimated $1.34M sold.

Mackay Shields LLC first reported a position in AIMT in Q2 2018 and held it in 7 quarters. The position peaked at $1.44M in Q2 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

Mackay Shields LLC reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
Mackay Shields LLC sold 39,891 Aimmune Therapeutics shares in Q1 2020, an estimated $1.34M.
Mackay Shields LLC first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 7 quarters.
Mackay Shields LLC's Aimmune Therapeutics position peaked at $1.44M in Q2 2019.
161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Mackay Shields LLC's 13F filing for Q1 2020, filed 8 May 2020.